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Abstract
Natural and complementary therapies in conjunction with mainstream cancer care are steadily gaining popularity. Ginger
extract (GE) confers significant health-promoting benefits owing to complex additive and/or synergistic interactions
between its bioactive constituents. Recently, we showed that preservation of natural ‘‘milieu’’ confers superior anticancer
activity on GE over its constituent phytochemicals, 6-gingerol (6G), 8-gingerol (8G), 10-gingerol (10G) and 6-shogaol (6S),
through enterohepatic recirculation. Here we further evaluate and compare the effects of GE and its major bioactive
constituents on cytochrome P450 (CYP) enzyme activity in human liver microsomes by monitoring metabolites of CYP-
specific substrates using LC/MS/MS detection methods. Our data demonstrate that individual gingerols are potent inhibitors
of CYP isozymes, whereas GE exhibits a much higher half-maximal inhibition value, indicating no possible herb-drug
interactions. However, GE’s inhibition of CYP1A2 and CYP2C8 reflects additive interactions among the constituents. In
addition, studies performed to evaluate transporter-mediated intestinal efflux using Caco-2 cells revealed that GE and its
phenolics are not substrates of P-glycoprotein (Pgp). Intriguingly, however, 10G and 6S were not detected in the receiver
compartment, indicating possible biotransformation across the Caco-2 monolayer. These data strengthen the notion that an
interplay of complex interactions among ginger phytochemicals when fed as whole extract dictates its bioactivity
highlighting the importance of consuming whole foods over single agents. Our study substantiates the need for an in-
depth analysis of hepatic biotransformation events and distribution profiles of GE and its active phenolics for the design of
safe regimens.
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Introduction
The practice of integrative oncology, especially, inclusion of
complementary and alternative plant-derived agents for chemo-
therapeutic and chemopreventive gains is steadily increasing
among cancer patients’. While most of these dietary agents like
spices, herbs and whole food extracts are categorized as Generally
Regarded As Safe (GRAS) Agents, US FDA requires that these
agents are not harmful in their intended conditions of use (i.e.,
consumption as therapeutic agents), are generally available and
are associated with scientific evidence to establish their safety [1].
Although these dietary agents appear to be safe and well tolerated,
their consumption with conventional chemotherapy and other
drug regimens can be complex and can result in health
complications. This is primarily because their pharmacodynamic
and pharmacokinetic responses are either attenuated or enhanced
depending on their metabolism and transport in physiological
systems [2]. Some commonly used spices (curcumin, clove, and
piperine), fruits (grape fruit, orange and cranberry) and vegetables
(spinach, tomato and carrot) when administered for a long time
are known to improve or fail treatments employing conventional
drugs [3]. For example, interactions of drugs like ergotamine and
nimodipine with grapefruit juice are known to cause gangrene or
stroke [4]. On the other hand, consuming dietary supplements like
St. John’s wort [5], and grapefruit juice [6–8] with drugs like
terfenadine, cyclosporine, atorvastatin and lovastatin resulted in
their increased blood plasma levels resulting in undesirable/toxic
side effects. Their individual effects on drug metabolizing enzymes
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and various uptake and efflux transporters influence the extent of
interactions between these plant-based agents and conventional
drugs.
The pharmacokinetic and pharmacodynamic interactions of
dietary agents are due to their being substrates of Phase I and II
metabolizing enzymes and drug transporters. Majorly, cytochrome
P450 (CYP450) enzymes are involved in the phase I biotransfor-
mation of xenobiotics like drugs, food components, environmental
toxins and other endogenous substances via their modification into
corresponding metabolites [9]. CYP enzymes are highly expressed
in human liver (including CYP1A2, CYP2A6, CYP2B6,
CYP2C8/9/19, CYP2D6, CYP2E1 and CYP3A) and are
responsible for 95% of drug metabolism [10,11]. As the
metabolism of a drug can be altered by another co-administered
drug, which may prove to be clinically significant, it is important to
establish the nature of interactions of a drug/herb/phytochemical
i.e., if it is a substrate, inhibitor or inducer of specific CYP and
other phase II conjugating enzymes and a substrate for uptake or
efflux transporter(s) [9,12]. Furthermore, inhibition of CYP
enzyme activity by a dietary constituent can significantly increase
the toxic effect of a drug (e.g. grapefruit juice and terfenadine) [4],
which necessitates evaluation of potential drug-dietary constituent
interactions. On the other hand, transport across gastrointestinal
(GI) membrane also plays a key role in the biotransformation and
associated activity of xenobiotics [13,14]. Their absorption across
the gut wall via passive diffusion or active uptake does not always
coincide with improved bioavailability, as they may be exposed to
a variety of efflux pumps including the ATP-binding cassette
(ABC) transporters like P-glycoprotein (Pgp), multidrug resistance-
associated protein 2 (MRP2) and breast cancer resistance protein
(BCRP), which are actively involved in the transport of molecules
back into the GI lumen [14]. This efflux mechanism in vivo is
primarily responsible for poor absorption of drugs affecting their
clinical development irrespective of their remarkable in vitro
efficacy [13,14]. It has also been reported that several food-drug
interactions occur due to the ability of the food components to
upregulate or inhibit the trasporter efflux pumps thus regulating
the bioavailability of pharmaceutical agents [13].
Over the past few decades, substantial research has been
dedicated to study the therapeutic benefits of dietary constituents,
mainly plant-based food extracts and spices, which has proven to
be beneficial with the discovery of disease-fighting efficacies of
several whole foods and their constituent phytochemicals. Ginger
is one such extensively studied spice whose therapeutic gains have
encouraged its worldwide consumption [15]. Ginger extract (GE)
containing a variety of active phytochemicals like 6-, 8-, and 10-
gingerol, 6-paradol, 6- and 10-shogaol, zingerone, 6- and 10-
gignerdione, 10-gingerdiol, 6-hydroxyshogaol, 6, 8-, and 10-
dehydroshogaol and diarylheptanoids [16,17], has been the spice
of immense interest in the recent times. Extensive research on its
active constituents, 6-gingerol (6G), 8-gingerol (8G), 10-gingerol
(10G) and 6-shogaol (6S) has shown that GE and its components
possess antioxidative, anti-inflammatory and anticancer efficacies
[18–22]. Further, it has been reported that in humans upon
consuming as low as 2 g of GE, gingerols were found to be
circulating in the system (6G: 0.8560.43 mg/mL, 8G:
0.2360.16 mg/mL, 10G: 0.5360.40 mg/mL, 6S: 0.1560.12 mg/
mL) albeit as their glucuronide and sulfate conjugates [23,24].
Our laboratory is the first to identify and evaluate the
anticancer activity of GE in both in vitro and in vivo prostate
xenograft models [25]. We further established that the anticancer
efficacy delivered by the phytochemical-rich GE is majorly due to
the additive and/or synergistic interactions among its constituent
biophenolics [26]. Recently, we reported that upon oral delivery of
GE, its active constituents, including 6G, 8G, 10G and 6S,
undergo enterohepatic recirculation for optimal therapeutic
activity [27]. Also, a pharmacodynamic and pharmacokinetic
comparison between the whole GE and a quasi mixture (known as
Mix), formulated by combining the active GE constituents, 6G,
8G, 10G and 6S, in amounts equivalent to those present in the
natural form (GE) suggested that the active phenolics collaborate
with other GE constituents to effectively elicit sustained antitumor
efficacy [27].
As the next obvious step of our multi-series GE study, we asked
if GE and its active phenolics could modulate the hepatic
biotranformation enzyme systems, particularly the CYP enzyme
activity. Given that GE can potentially be included in the arsenal
of GRAS agents for cancer management, it is crucial that its CYP
inhibition profile is well studied to preclude any adverse drug
interaction events. Here we demonstrate the effect of GE and its
active phenolics on the CYP450 enzyme system and its possible
biotransformation during intestinal transport. As we previously
observed [27] that ginger phenolics undergo extensive conjugation
in the intestine and/or liver upon oral administration of GE, we
also assessed their apparent permeability to evaluate the effects of
Pgp and BCRP efflux pumps on their bioavailability.
Materials and Methods
Cell Line and Reagents
Human liver microsomes (mixed gender, pool of 50 donors)
were procured from XenoTechLLC (Kansas, USA; protein
content: 20 mg/mL; catalogue number: H0610). Standard sub-
strates and inhibitors were procured from Sigma-Aldrich, India,
US Biologicals and Acros Organics. All the stable labeled internal
standard(s) (IS) were from Toronto Research Chemicals, Canada.
NADPH, formic acid, ammonium formate, sodium dihydrogen
phosphate and disodium hydrogen phosphate, 12-well Corning
Transwell filters, HBSS, HEPES, glucose, dimethyl sulfoxide
(DMSO) and sodium bicarbonate were purchased from Sigma
Aldrich, India. Acetonitrile (ACN) was from Merck, India. Milli-Q
water (Millipore Corporation, India) was used for preparation of
buffer. 96-well plates of 1 mL capacity were purchased from
Axygen Scientific, USA. All gingerols and GE were isolated as
previously described [27]. Caco-2, human colon carcinoma
epithelial cell line was obtained from ATCC (HTB-37, Manassas,
USA) and cells were used at passage number 40. Milli-cell
apparatus from Millipore was used to measure the TEER.
CYP Inhibition Assay
Preparation of Stock Solutions. 20 mM stock solutions of
6G, 8G, 10G and 6S were prepared in ACN:DMSO::80:20
mixture and subsequent test dilutions of inhibitor (final concen-
trations of 100, 50, 25, 12.5, 6.25, 3.125, 1.563, 0.781, 0.390,
0.195 and 0.098 mM) were prepared in ACN:DMSO::80:20.
100 mg of ginger extract containing 3 mg of 6G, 0.680 mg of 8G,
0.770 mg of 10G and 0.590 mg of 6S was extracted with 1 mL of
ACN:DMSO (80:20), vortex mixed for 3 min followed by
sonication for 3 min and centrifuged at 5000 g for 5 min. The
supernatant was collected and used for CYP inhibition assay. The
highest concentration of GE used in the assay was 500 mg/mL
equivalent. Stock solution for each CYP specific probe substrate
was prepared in such a way that the final concentration is below
the reported Km value. Recommended inhibitor stock solutions
were prepared in ACN:DMSO mixture (80:20) as given in Table
S1 in File S1.
Assay Incubations. A microsome-buffer-substrate mixture
(MBS mix) was prepared for each isozyme by pre-mixing
CYP Inhibition and Permeability of Gingerols
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appropriate volumes of sodium phosphate buffer (pH 7.4,
50 mM), microsomes and substrate (Table S2 in File S1).
179 mL of MBS mix was transferred to 96-well reaction plate to
which 1 mL of inhibitor stock solution was added to achieve the
final target inhibitor concentration. The reaction plate was pre-
incubated for 10 min at 37uC followed by reaction initiation by
addition of 20 mL of 10 mM NADPH solution. The reaction plate
was then incubated at 37uC for a predetermined time period
following which it was quenched with 200 mL ACN for all CYPs
and 200 mL 1% formic acid in water:ACN (70:30) for CYP1A2. In
all cases, the final incubations after addition of substrate and
inhibitor contained 0.1% DMSO (v/v), and the total organic
solvent (DMSO and ACN) content was less than or equal to 1%
(v/v). The details of final substrate concentration, incubation time,
microsomal protein concentration in the reaction mixtures and the
metabolites monitored for each isozyme tested are presented in
Table S3 in File S1. The incubations were performed in singlet for
individual gingerols and in duplicate for GE along with respective
positive controls.
Bioanalysis. All samples were processed using protein
precipitation method and analyzed by employing positive (for all
CYPs) and negative (for CYP2A6, 2C19 and 2E1) ionization mode
in liquid chromatography tandem mass spectrometry (API4000,
Applied Biosystems, USA). The peak area ratio of analyte to IS
was used for calculations. An isocratic method comprising 5 mM
ammonium formate and ACN (40:60) with 0.05% formic acid was
used for elution. For CYP2C19, a mobile phase consisting of
5 mM ammonium formate and ACN (30:70) was used. The
analytes and internal standards were retained on BDS Hypersil
Phenyl (15064.6 mm, 5 m, Thermo, USA) column. A flow rate of
0.5 mL/min (CYP1A2), 0.6 mL/min (CYP2C19, CYP2E1),
0.7 mL/min (CYP2C9), 0.8 mL/min (CYP2A6, CYP3A),
1.0 mL/min (CYP2B6, CYP2C8, CYP2D6) was maintained using
Shimadzu Prominence solvent delivery system (LC-20AD). The
mobile phase was degassed using degasser (DGU-20A3), samples
were loaded into autosampler (SIL-HTc) and the column
temperature was maintained at 40uC by column oven (CTO-
20A). Injection volumes for the samples were as follows: 5 mL
(CYP1A2, CYP2D6, and CYP3A), 10 mL (CYP2B6, CYP2C8,
and CYP2E1) and 20 mL (CYP2A6, CYP2C9, and CYP2C19).
Data was collected and processed using Sciex Analyst 1.4.2. The
mass transition, retention time, ionization mode for each
metabolite and IS are presented in Table S4 in File S1. All the
structures of inhibitors, substrates, metabolites and internal
standards for each CYP enzyme are represented in Table S6 in
File S1.
Data Analysis. The IC50 value was estimated from the
percentage reduction in CYP activity at eleven inhibitor concen-
trations with respect to control. The area ratio of the metabolite in
the sample without inhibitor was considered as 100%, and the
percentage reduction in the CYP activity at each inhibitor
concentration was determined relative to the no-inhibitor area
ratio using the following equation:
%CYP activity~
Area ratio of metabolite at each dilution
Area ratio of no - inhibitor controls
|100
The non-linear regression model in GraphPad Prism software was
used to analyze the percent CYP activity data at different
concentrations and the data were fitted to the following equation
and IC50 was calculated:
Y~Bottomz½(Top{Bottom)=1z10(fLogIC50{XgHillcoefficient)
Where, X=Log concentration; Y=Response (% CYP activity)
The data was analysed using 4PL (parameter logistic model),
3PLFB (bottom fixed), 3PLFT (top fixed), 2PL (top and bottom
fixed), and the relative IC50 was with lowest standard error was
further manipulation. Absolute IC50 was calculated from this
relative IC50 by using the equation below:
Absolute IC50~Relative IC50=½ftop{bottomg=
f(50{bottom){1g1=slope
Caco-2 Permeability Assay
Preparation of Cell Monolayers. Caco-2 cells were seeded
on tissue culture inserts at a density of 80,000 cells/insert. The
cells were maintained for 21 days in culture medium to enable
differentiation and formation of the monolayer. The culture
medium was changed every alternate day.
Preparation of Stock Solutions and Buffers. Stock solu-
tions (1 mM) of individual gingerols were prepared in DMSO,
which were then spiked into the buffer to obtain a final assay
concentration of 10 mM. HBSS-HEPES buffer was prepared by
dissolving 9.7 g Hank’s balanced salts, 0.37 g sodium bicarbonate,
3.50 g glucose and 2.38 g HEPES in Milli-Q water (1 L). The pH
of the buffer was adjusted to 7.4 using either 1N hydrochloric acid
or 1N sodium hydroxide.
Transport Assay. Permeability of gingerols (10 mM) was
determined in apical to basolateral (A-B) and basolateral to apical
(B-A) directions. Transport studies were conducted between 21–25
days post seeding in 12-well Transwell inserts. Following pre-
incubation in HBSS-HEPES buffer at 37uC, 5% CO2 for 30 min,
buffer was removed and gingerols spiked buffer was added to each
donor compartment (triplicate wells). Blank HBSS-HEPES buffer
containing 1% DMSO was added to the receiver compartment.
Samples were withdrawn from the receiver chamber at 30, 60, 90,
and 120 min, and from the donor chamber at 0 and 120 min. The
samples were collected in tubes containing equal volume of ACN.
The withdrawn volume was replaced with buffer containing 1%
DMSO. At the end of the experiment, cells were washed with ice-
cold buffer and lysed with ACN to assess cell accumulation and
estimate the recovery. Monolayers with transepithelial electrical
resistance (TEER) above 300 Vcm2 were considered for the assay
and after the assay TEER values were above 300 Vcm2
confirming the monolayer integrity during the experiment.
Bioanalysis. Samples were processed using protein precipi-
tation method and analyzed using LC/MS/MS. A calibration
curve (CC) of 5 nM to 10,000 nM range was employed to quantify
the samples. 8G, 10G and 6S were eluted using a mobile phase
consisting of ACN:5 mM ammonium formate (80:20) with 0.05%
formic acid and for 6G, a mobile phase of ACN:Milli-Q water
(80:20) with 0.1% formic acid was used. Separation was achieved
using Zorbax C18 column (5064.6 mm, 3.5 m, Agilent) for 8G,
10G, 6S and using Hypurity C18 column (10064.6 mm, 5 m,
Thermo) for 6G. An injection volume of 20 mL was used for all
samples and a flow rate of 0.6 mL/min (6G) and 1 mL/min (8G,
10G and 6S) was used for elution. The MRM transitions (m/z)
monitored were: 6G (312.3/177.1), 8G (340.0/177.1), 10G
(333.0/177.1), 6S (277.2/137.1) and rolipram (276.2/208.2,
Internal standard, 100 ng/mL).
CYP Inhibition and Permeability of Gingerols
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Data Analysis. Cumulative amount of gingerols transported
at each time point was plotted as function of time. The slope was
used to calculate the rate of appearance of gingerols (dQ/dt).
Apparent permeability (Papp) was calculated using the formula
Papp~(dq=dt)=(A X C0)
dQ/dt – rate of transport to receiver side
A - surface area of the membrane 1.12 (cm2)
C0 - initial concentration
Statistical Analysis
CYP inhibition experiments for GE were conducted in
duplicate and active phenolics in singlet. Mean IC50 values of
GE and positive controls are presented in the result table.
Permeability experiments were run in triplicates and the data are
expressed as mean 6 standard deviation (SD).
Results
To ascertain the nature of interactions that ginger biophenolics
undergo during Phase I metabolism when delivered individually
and/or in their natural form, we incubated GE, 6G, 8G, 10G and
6S with human liver microsomes at different concentrations and
evaluated their CYP enzyme inhibitory activity. The highest
concentration tested for GE was 500 mg/mL (containing 15 mg/
mL 6G, 3.4 mg/mL 8G, 3.9 mg/mL 10G, 3.0 mg/mL 6S). All
individual components of gingerols were assessed at 100 mM
equivalent to 29 mg/mL 6G, 32 mg/mL 8G, 35 mg/mL 10G and
28 mg/mL of 6S. In brief, the CYP inhibition potential of 6G was
assessed at 2-fold higher concentration than that is present in GE
and for 8G, 10G and 6S the CYP inhibition potential was assessed
at 10-fold higher concentration than the constituent concentra-
tions within GE. We next asked if GE and/or its active
biophenolics inhibit the major membrane-bound players of
CYP450 enzyme system, namely CYP1A2, CYP2A6, CYP2B6,
CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A
enzymes. The effects of GE in comparison to its active constituents
on various CYP enzymes tested in this study are summarized here
below.
CYP1A2
CYP1A2 isozyme is involved in the activation of procarcinogens
and thus is implicated in the induction of carcinogenesis [28].
Upon incubation of human liver microsomes with GE and its
active phenolics in the presence of phenacetin, CYP1A2, found in
lung, oesophagus, stomach colon and primarily expressed in the
liver [29], was found to be inhibited by GE with an IC50 of
221.5 mg/mL (Fig. 1A, Table S5 in File S1) and the corresponding
6G (5.6 mg/mL), 8G (8.8 mg/mL), 10G (.35 mg/mL) and 6S
(0.7 mg/mL) IC50 values were similar to the concentrations of their
respective counterparts present in GE (Fig. 1A, Table S5 in File
S1). Nonetheless, their CYP1A2 inhibiton activity was at least
,700–35000 fold lower than a-naphthoflavone, the positive
control simulataneously tested, suggesting that in general GE
and its active consituents are not potent inhibitors of CYP1A2.
CYP2 Family
CYP2 is the largest CYP450 family in mammals including 13
subfamilies and 16 genes and is involved in the oxidation of a
Figure 1. Effects of GE and its active constituents on the activity of (A) CYP1A2 with substrate, phenacetin and (B) CYP2A6 with
substrate, coumarin upon incubation with human liver microsomes. The corresponding positive controls (Ai) naphthoflavone and (Bi)
tranylcypromine activities were tested followed by (Aii, Bii) 6G, 8G, 10G, 6S and (Aiii, Biii) GE. Data shown are averages of duplicate experiments for GE
and positive controls.
doi:10.1371/journal.pone.0108386.g001
CYP Inhibition and Permeability of Gingerols
PLOS ONE | www.plosone.org 4 September 2014 | Volume 9 | Issue 9 | e108386
majority of pharmaceutical agents [29]. Most CYP2 enzymes are
preferentially expressed in extrahepatic tissues, specifically in
epithelia and mainly metabolize endogenous substrates [30]. GE
was found to have no effect on CYP2A6 enzyme, previously
known as coumarin hydroxylase, even at the highest concentration
(500 mg/mL) tested, while individual gingerols and shogaol
showed minimal inhibitory effect with IC50 value greater than
19 mg/mL (Fig. 1B, Table S5 in File S1) in the presence of
coumarin. The positive control, tranylcypromine, was ,4000 fold
more effective than the test compounds with an IC50 value of
8.4 ng/mL.
Further analysis for CY2B6, another enzyme involved in
metabolizing nicotine along with CYP2A6 [12,29], revealed that
GE showed the maximum inhibition on CYP2B6 with an IC50
value of 22 mg/mL (Fig. 2A, Table S5 in File S1) in the presence
of bupropion. The three gingerols and shogaol exhibited ,100–
1000 fold lower inhibition of CYP2B6 with half-maximal
inhibitory concentrations varying from 1.5–15 mg/mL (Fig. 2A,
Table S5 in File S1) compared to ticlopidine, the positive control.
Also, the inhibitory activity of GE seemed due to the contribution
other partners present in GE apart from the 4 active phenolics.
Next, we evaluated the effects of GE and its active phenolics on
the CYP2C subfamily including CYP2C8, CYP2C9 and
CYP2C19, which are known to jointly metabolize more than 50
clinical drugs [12,29,31]. Detected mainly in stomach and small
intestine, these enzymes colocalize in the endoplasmic reticulum
[12]. GE showed an IC50 value of 122.5 mg/mL against CYP2C8
in the presence of amodiaquine, while 6G exhibited an IC50 value
of 6.5 mg/mL (Fig. 2B, Table S5 in File S1). On the other hand,
8G, 10G and 6S were as potent as the positive control, quercetin
(370 ng/mL), indicating a possibility of drug-drug interactions in
the event of co-administration of individual gingerols and shogaols
with other conventional prescription drugs. However, upon
delivering these ginger biophenolics in their native form, i.e., as
GE, there seemed to be neither a synergistic nor additive effect
suggesting that other GE phenolics are involved in annulling the
unfavorable inhibitory effect on CYP2C8 (Fig. 2B, Table S5 in
File S1). GE showed an IC50 value 93.5 mg/mL against CYP2C9,
in presence of diclofenac, the specific CYP2C9 substrate. The
active ginger phytochemicals exhibited inhibitory concentrations
similar to the each individual counterpart’s contribution when
present in GE, confirming the additive effect in inhibiting
CYP2C9. The inhibitory effect of the active constituents was
,10 to 100 fold lower than sulfaphenazole (72.7 ng/mL), the
positive control (Fig. 3A, Table S5 in File S1). On the contrary,
active GE phenolics showed inhibition which was ,3 to 10 fold
lower compared to 6N-3-benzylnirvanol (320 ng/mL) against
CYP2C19 in the presence of (s)-mephenytoin (Fig. 3B, Table S5 in
File S1). GE also exerted an inhibitory effect at equivalent
concentrations as observed in case of the active constituents
(35.5 mg/mL, Fig. 3B, Table S5 in File S1).
We next analyzed the effects of GE and its constituent active
phenolics on CYP2D6, the enzyme involved in the metabolism of
several endogenous substances and about 25% of marketed drugs
[29,32]. In the presence of dextromethorphan (substrate), the
positive control, quinidine, inhibited CYP2D6 with an IC50 value
of 54 ng/mL. In comparison, the active GE phenolics exhibited
,350 to 550 fold lower activity, while GE showed no signs of
inhibition at the highest concentration tested (.500 mg/mL,
Fig. 4A, Table S5 in File S1). A similar effect on CYP2E1 enzyme,
Figure 2. Effects of GE and its active constituents on the activity of (A) CYP2B6 with substrate, bupropion and (B) CYP2C8 with
substrate, amodiaquine upon incubation with human liver microsomes. The corresponding positive controls (Ai) ticlopidine and (Bi)
quercetin activities were tested followed by (Aii, Bii) 6G, 8G, 10G, 6S and (Aiii, Biii) GE. Data shown are averages of duplicate experiments for GE and
positive controls.
doi:10.1371/journal.pone.0108386.g002
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PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e108386
detected in abundance in lung, oesophagus and small intestine,
was observed with GE, showing no effect even at 500 mg/mL
(Fig. 4B, Table S5 in File S1). Also, the active GE constituents
showed no inhibiton (,40–70 fold lower inhibition compared to
positive control tranylcypromine, IC50 is 579 ng/mL) (Fig. 4B,
Table S5 in File S1).
Next, we analyzed the effect of GE and its active phenolics on
the most abundant CYP450 enzyme, CYP3A. This enzyme highly
expressed in human liver and gastrointestinal tract [33,34] is
known to metabolize more than 55% of clinical drugs [35].
Inhibition of CYP3A is reported to significantly increase the
exposure of drugs, therefore resulting in an increased risk of
adverse drug reactions [35]. Several dietary agents, including
grape fruit juice are known to inhibit CYP3A enzymes [6]. We
employed two substrates, midazolam and testosterone, which bind
to different active sites on CYP3A, to determine the effect of GE
and its biophenolics on enzyme activity. In the presence of
midazolam, GE did not affect the enzymatic activity of CYP3A
and individual constituents also showed similar profile (IC50 18–
35 mg/mL) (Fig. 5A, Table S5 in File S1). In presence of
testosterone, the constituent biophenolics of GE showed inhibition
of CYP3A activity with IC50 values ranging from 2.3 to 11 mg/mL
(Fig. 5Bii, Table S5 in File S1). Further, the inhibition of CYP3A
by GE (Fig. 5Biii, Table S5 in File S1) in the presence of
testosterone confirmed the contribution of the active constituents.
The constituent phenolic compounds of GE are small organic
molecules, which must be absorbed into the systemic circulation to
be carried across the blood stream to target tissues and organs.
Essentially, the pharmacological activity of xenobiotic compounds
mainly depends on their sustained levels at the sites of action and/
or their active metabolites. In order to attain sufficient effective
concentrations at the target site, the orally ingested compounds
have to overcome certain barriers including efflux, solubility, pH
and metabolism [36,37]. In addition, the absorption, distribution,
metabolism and excretion (ADME) processes dictate their target-
site concentration [38,39]. Uptake of active molecules by
enterocytes via passive diffusion or active transport is crucial for
their biodistribution [2,40]. However, favorable absorption of
these phenolic compounds across the gut does not translate to their
improved bioavailability and efficacy [37,40]. Upon being
absorbed by the enterocyte, the active constituents are usually
presented as substrates to various efflux pumps like ATP-binding
cassette (ABC) transporters, P-glycoprotein (Pgp), multidrug
resistance-associated protein 2 (MRP2), and breast cancer
resistance protein (BCRP), which can actively transport them
back into the intestinal lumen [13,40,41]. Hence, we next asked if
GE biophenolics serve as substrates of these efflux transporters
expressed in Caco-2 cells, which will prevent them from crossing
the intestinal membrane, thus leading to attenuated activity and
decreased bioavailability. To this end, Caco-2 monolayers were
treated with active ginger constituents (10 mM) followed by
permeability assessment in apical to basolateral and basolateral
to apical direction by measuring the transepithelial electrical
resistance (TEER).
GE Biophenolics Undergo Possible Biotransformation
Evaluation of in vitro transport profile of the active ginger
constituents revealed that the apparent permeability (Papp) of 6G,
the most abundant gingerol in GE, was greater than 100 nm/sec
in both apical to basal (ARB) and basal to apical (BRA)
Figure 3. Effects of GE and its active constituents on the activity of (A) CYP2C9 with substrate, diclofenac and (B) CYP2C19 with
substrate, (s)-mephenytoin upon incubation with human liver microsomes. The corresponding positive controls (Ai) sulfapenazole and (Bi)
benzylnirvanol activities were tested followed by (Aii, Bii) 6G, 8G, 10G, 6S and (Aiii, Biii) GE. Data shown are averages of duplicate experiments for GE
and positive controls.
doi:10.1371/journal.pone.0108386.g003
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directions. The efflux ratio in this case was less than 2 confirming
no possible role of efflux transporters like Pgp and BCRP in 6G’s
disposition. However, the recovery from ARB was less than 50%
and BRA was 77% with no intracellular accumulation (,5%)
(Table 1). Further, Papp of 8G was 53 nm/sec in ARB and
69 nm/sec in BRA direction. With an efflux ratio of 1.3, there
seemed to be no interference from any efflux transporters in 8G’s
permeability, while its recovery in both directions was less than
60% with no cell accumulation (,1%).
Interestingly, the Papp of 10G was lower than other active
phenolics, i.e. 9 nm/sec in ARB and 17 nm/sec in B-A direction
and the recovery in both directions was less than 50%, suggesting
chances of metabolism with some accumulation (15%) in cells. 6S
exhibited the lowest recovery, less than 25% in both directions
indicating a possible biotransformation and apparent permeability
values were 0.71 nm/sec and 4 nm/sec in ARB and BRA
directions, respectively. However, there was almost no accumu-
lation of 6S in cells (Table 1).
Discussion
Phytocomplexity of ginger extract (GE) dictates the intricate
synergistic or additive interactions between its constituent bioac-
tive phenolics and thus explains the attenuation of bioactivity
when single components are isolated. Essentially, the bioactivity of
whole GE can perhaps be ascribed to an interaction of the
biological system with multiple active compounds present in GE at
low to undetectable levels. While the exact spectrum of bioactive
components of GE is not fully defined, a large number of
pharmacologically active compounds have been isolated and
purified in various laboratories including ours. The oral bioavail-
ability of GE and other such plant-based extracts is associated with
many presystemic processes, including solubility and stability in
gastrointestinal fluid, membrane permeability, transporter [e.g. P-
glycoprotein (Pgp/MDR1/ABCB1)]-driven intestinal efflux, pre-
systemic gut wall metabolism and presystemic hepatic metabolism.
Suboptimal intestinal absorption of food-based extracts may occur,
leading to low oral bioavailability.
With growing focus on employing alternative medicine, mainly
dietary agents, as chemopreventive and chemotherapeutic agents
in order to reduce the toxicity rendered by the current clinical
drugs, food-drug interactions have been a major concern in
regarding them as safe for consumption. Dietary supplements,
when coadministered with conventional drugs, have been found to
effect the latter’s pharmacokinetic and pharmacodynamics inter-
actions [6–8,29,42,43]. Furthermore, as these interactions majorly
involve metabolism and transport of drug molecules, co-admin-
istration with dietary agents could result in altering the activity of
drug-metabolizing enzymes [2,44]. Although they are ‘‘natural’’
and therefore considered as ‘‘safe’’, little is known about the effects
their constituents may have on the co-administered medication.
Furthermore, it is crucial to understand the absorption, distribu-
tion, metabolism and excretion processes of such plant-derived
agents to facilitate their development as dietary supplements.
Polyphenols in our diet have been implicated in affecting the blood
plasma concentrations of clinical drugs, thus resulting in either
increased exposure or loss of their therapeutic effects [45–47].
Having shown the remarkable chemotherapeutic efficacy of GE,
Figure 4. Effects of GE and its active constituents on the activity of (A) CYP2D6 with substrate, dextromethorphan and (B) CYP2E1
with substrate, chlorzoxazone upon incubation with human liver microsomes. The corresponding positive controls (Ai) sulfapenazole and
(Bi) tranylcypromine activities were tested followed by (Aii, Bii) 6G, 8G, 10G, 6S and (Aiii, Biii) GE. Data shown are averages of duplicate experiments for
GE and positive controls.
doi:10.1371/journal.pone.0108386.g004
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possibly due to enterohepatic recirculation of the active biophe-
nolics [27], questions related to their impact on drug metabolizing
enzymes led us to our current investigation.
Our study revealed that GE and its active constituents (6G, 8G,
10G and 6S) caused inhibition of CYP isozymes, in the order:
CYP2B6.CYP2C19.CYP2C9.CYP2C8.CYP3A (testoster-
one as substrate).CYP1A2 (Fig. 1A, 2A–B, 3A–B, 5B, Table S5
in File S1). GE showed the highest inhibitory effect on CYP2B6
(IC50 = 22 mg/mL) among all the tested CYPs, against which its
active constituents showed no inhibition (Fig. 1B, 4A–B, 5A, Table
S5 in File S1). This effect could be due to the partnering
constituent(s) in GE other than 6G, 8G, 10G and 6S, which might
be inhibitors of CYP2B6. Furthermore, the inhibitory effect of GE
on CYP2C8, CYP2C9 and CYP2C19 seems to be primarily due
to additive interactions among the constituent active phenolics
(Table S5 in File S1). Recent reports indicate that in humans, the
major components of GE (6G, 8G, 10G and 6S) are present as
glucuronide and sulfate conjugates while free forms were observed
in the blood plasma only upon oral administration at a high dose
of 2 g per subject [23,24]. Our current study compares the Cmax of
various gingerols reported by Zick et al in humans with the IC50
values from our CYP inhibition assay. The Cmax of 6G was
0.85 mg/mL and the lowest IC50 value observed was with
CYP2C19 (3.2 mg/mL) and for 8G, Cmax was 0.23 mg/mL and
lowest inhibitory concentration was with CYP2C8 (0.70 mg/mL).
Similarly for 10G, Cmax was 0.53 mg/mL and lowest IC50 value
was with CYP2B6 (1.5 mg/mL) while Cmax for 6S was 0.15 mg/
mL and it was found to be most active against CYP1A2 (0.70 mg/
mL). This comparison reveals that the highest blood plasma
concentration attained for these active ginger phenolics is at least
3–4 fold lower than their respective CYP450 enzyme inhibitory
concentrations in vitro (for CYP2C8 and CYP1A2, it was 2-fold
lower). This suggests that physiologically these active GE phenolics
might be incapable of modulating the Phase I metabolizing
enzymes. Clearly, these plasma concentrations achieved in
humans are insignificant in case of GE (Table S5 in File S1) to
inhibit CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A.
Also, inhibition of CYP isozymes seems to be additive than
synergistic and the active GE phenolics also prone to extensive
conjugation in humans at intestinal level followed by liver. The
overall effect of CYP inhibition by GE may be clinically irrelevant
with respect to co-administered drugs that susbtrates of CYP
isozymes.
Furthermore, our attemps to determine if the absorption of GE
phenolics is affected by the efflux pumps across gastrointestinal
membrane revealed that in the Caco-2 monolayer, permeability of
6G was highest followed by 8G, 10G and 6S (Table 1). Recovery
of all the gingerols from the apical to basal side was less than 50%,
which was lower than basal to apical side transport with no
significant cell accumulation (Table 1). This difference could be
due to extensive glucuronidation or sulfation of the ginger
constituents across the Caco-2 monolayer [48,49], supporting
our previous data suggesting possible intestinal glucuronidation of
6G, 8G, 10G and 6S followed by their enterohepatic recirculation
when in their native form to impart maximum efficacy to GE [27].
8G and 10G were recently shown to inhibit CYP3A4
expression, thus implicating their use in combination therapies
[50]. Human intestinal microsomal content is around 10 times
lower compared to the liver. While the intestinal CYPs are CYP3A
(80%), CYP2C (16%), CYP2J2 (,2%) and CYP2D6 (,1%), in
liver they are, CYP3A (40%), CYP2C (25%), CYP1A2 (18%),
CYP2E1 (9%), CYP2A6 (6%), CYP2D6 (2%) and CYP2B6 (,1%)
Figure 5. Effects of GE and its active constituents on the activity of CYP3A4 with substrates, (A) midazolam and (B) testosterone
upon incubation with human liver microsomes. The corresponding positive control, (Ai and Bi) ketoconazole’s inhibitory activity was tested
followed by (Aii, Bii) 6G, 8G, 10G, 6S and (Aiii, Biii) GE. Data shown are averages of duplicate experiments for GE and positive controls.
doi:10.1371/journal.pone.0108386.g005
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[51,52]. Clearly, as no major interaction was observed in case of
GE and CYP3A (Fig. 5A–B, Table S5 in File S1), the most
abundant CYP in liver and intestine, and also considering the
Cmax data in humans for these ginger constituents, any major
food-drug interactions involving the substrates of CYP3A are not
foreseen. Further, we even speculate that only those drug
molecules, which undergo conjugation reactions in the intestine
and/or liver may succumb to drug-ginger interactions. This is
because, it has been observed that ginger phenolics undergo
extensive glucuronidation and sulfation in vivo [23,27]. This is
even further supported by our current observations where the
recovery of gingerols was low (Table 1) across the Caco-2 cell
monolayer, which is known to express uridine diphosphate
glucuronosyltransferases (UGTs) and sulfotransferases (SULTs)
[53–56], thus indicating their possible biotransformation. Howev-
er, the loss in recovery of ginger constituents could also be due to
lower solubility of gingerols in assay buffer and non-specific
binding to assay plate, hence prompting further investigation to
determine the reason for loss in recovery.
Also, as literature reports suggest that CYP1A2 is involved in
the induction of carcinogenesis by metabolizing procarcinogens
[29,57,58], the role of GE in modulating this particular enzyme
requires further scrutiny. Dietary agents like cabbages, cauliflower
and broccoli are known to induce the expression of CYP1A2 in
humans [29,59]. Furthermore, use of ingredients like cumin and
turmeric in most of the South Asian cuisines is linked to lower
activity of CYP1A2 [60]. Though our observations do not indicate
the induction role of GE, our data clearly suggests that GE could
inhibit CYP1A2 enzymatic activity (IC50 = 222 mg/mL, Table S5
in File S1) if higher concentrations of 6S were to be achieved in
vivo. In humans, among all GE constituents, concentration of 6S
was lowest (0.15 mg/mL) with propensity for both glucuronidation
and sulfation. Therefore, the inhibitory activity due to 6S may be
limited on CYP1A2. Hence, further exploration of GE’s potential
in combination with other spice constituents to prevent carcino-
genesis and achieve improved anticancer efficacy seems logical.
In conclusion, our study highlights that GE and its active
constituents do not modulate CYP enzyme activity, suggesting no
potential prospective food-drug interactions, and thus rendering
GE as safe for dietary consumption. Our observations of possible
biotransformation of active ginger constituents across the Caco-2
monolayer are impelling and encourage investigation into the
bioactivity of the biotransformed metabolites. Futhermore, eval-
uation of the accumulation of these conjugates and/or metabolites
in the tumors and other tissues will aid in the design of futuristic
dietary combinations/supplements to improve GE’s anticancer
efficacy in prostate cancer management. Our studies constitute an
essential prestep before integrative medicine can be beneficial and
practised to its full potential.
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